These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 21326806

  • 1. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
    Dhingra S, Rodriguez ME, Shen Q, Duan X, Stanton ML, Chen L, Zhang R, Brown RE.
    Int J Clin Exp Pathol; 2010 Jan 28; 4(2):134-46. PubMed ID: 21326806
    [Abstract] [Full Text] [Related]

  • 2. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
    Shen Q, Stanton ML, Feng W, Rodriguez ME, Ramondetta L, Chen L, Brown RE, Duan X.
    Int J Clin Exp Pathol; 2010 Nov 20; 4(1):13-21. PubMed ID: 21228924
    [Abstract] [Full Text] [Related]

  • 3. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
    Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM.
    PLoS One; 2013 Nov 20; 8(7):e68985. PubMed ID: 23922674
    [Abstract] [Full Text] [Related]

  • 4. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.
    Mol Cell Biol; 2009 Mar 20; 29(6):1411-20. PubMed ID: 19114562
    [Abstract] [Full Text] [Related]

  • 5. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation.
    Liu J, Brown RE.
    Ann Clin Lab Sci; 2010 Mar 20; 40(3):211-7. PubMed ID: 20689131
    [Abstract] [Full Text] [Related]

  • 6. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
    Brewer Savannah KJ, Demicco EG, Lusby K, Ghadimi MP, Belousov R, Young E, Zhang Y, Huang KL, Lazar AJ, Hunt KK, Pollock RE, Creighton CJ, Anderson ML, Lev D.
    Clin Cancer Res; 2012 Sep 01; 18(17):4633-45. PubMed ID: 22821997
    [Abstract] [Full Text] [Related]

  • 7. Phospholipase D regulates the size of skeletal muscle cells through the activation of mTOR signaling.
    Jaafar R, De Larichaudy J, Chanon S, Euthine V, Durand C, Naro F, Bertolino P, Vidal H, Lefai E, Némoz G.
    Cell Commun Signal; 2013 Aug 02; 11():55. PubMed ID: 23915343
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.
    Quesada AE, Nguyen ND, Rios A, Brown RE.
    Int J Clin Exp Pathol; 2014 Aug 02; 7(12):8732-9. PubMed ID: 25674239
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes.
    Jaafar R, Zeiller C, Pirola L, Di Grazia A, Naro F, Vidal H, Lefai E, Némoz G.
    J Biol Chem; 2011 Jun 24; 286(25):22609-21. PubMed ID: 21525000
    [Abstract] [Full Text] [Related]

  • 12. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR.
    Lehman N, Ledford B, Di Fulvio M, Frondorf K, McPhail LC, Gomez-Cambronero J.
    FASEB J; 2007 Apr 24; 21(4):1075-87. PubMed ID: 17242159
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
    Zhang P, Zhang H, Wang Y.
    Cell Tissue Res; 2021 Feb 24; 383(2):865-879. PubMed ID: 33151453
    [Abstract] [Full Text] [Related]

  • 15. Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants.
    Liu J, Brown RE.
    Mod Pathol; 2011 Dec 24; 24(12):1553-9. PubMed ID: 21822208
    [Abstract] [Full Text] [Related]

  • 16. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.
    Int J Oncol; 2009 Oct 24; 35(4):731-40. PubMed ID: 19724909
    [Abstract] [Full Text] [Related]

  • 17. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
    Reis H, Hager T, Wohlschlaeger J, Bauer S, Katenkamp K, Katenkamp D, Baba HA.
    Hum Pathol; 2013 Oct 24; 44(10):2266-74. PubMed ID: 23871289
    [Abstract] [Full Text] [Related]

  • 18. Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid.
    Kam Y, Exton JH.
    FASEB J; 2004 Feb 24; 18(2):311-9. PubMed ID: 14769825
    [Abstract] [Full Text] [Related]

  • 19. NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma.
    Türkmen O, Müftüoğlu KH, Dinçer N, Çelik ZE, Akar Inan S.
    Turk J Med Sci; 2024 Feb 24; 54(4):804-810. PubMed ID: 39295619
    [Abstract] [Full Text] [Related]

  • 20. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, Uddin S, Al-Kuraya KS.
    Carcinogenesis; 2014 Jul 24; 35(7):1564-72. PubMed ID: 24583924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.